Bimekizumab

Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation[1].

Product Specifications

CAS Number

[1418205-77-2]

Product Name Alternative

Anti-Human IL17A/IL-17F Recombinant Antibody; CDP4940; UCB-4940

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bimekizumab.html

Purity

99.00

Solubility

10 mM in DMSO

Smiles

[Bimekizumab]

Molecular Weight

(147.24 kDa)

References & Citations

[1]Shah M, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020 Jul;6 (2) :e001306.